Skip to main content

Table 1 Demographic and clinical characteristics at baseline

From: Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden

  Infliximab I Etanercept II Level of significance
  MTX A Other DMARD B Mono-therapy C MTX A Other DMARD B Mono-therapy C  
Number 501 116 104 179 68 193  
Age (years) 55.0 (13.6) 57.4 (12.0) 61.0 (12.1) 53.4 (12.9) 54.0 (12.4) 57.7 (13.0) IC vs. IIC, p = 0.040
IIA vs. IIC, p = 0.003
IA vs. IC, p < 0.001
IB vs. IC, p = 0.027
Female 74% 75% 78% 78% 84% 84%  
Disease duration (months) 133.5 (113.8) 165.4 (118.5) 192.9 (132.4) 132.8 (107.3) 180.1 (115.1) 185.3 (121.4) IIA vs. IIC, p < 0.001
IIA vs. IIB, p < 0.001
IA vs. IB, p = 0.002
IA vs. IC, p < 0.001
HAQ score 1.34 (0.62) 1.57 (0.58) 1.69 (0.58) 1.30 (0.61) 1.61 (0.58) 1.60 (0.65) IIA vs. IIB, p < 0.001
IIA vs. IIC, p < 0.001
IA vs. IB, p < 0.001
IA vs. IC, p < 0.001
DAS28 5.5 (1.2) 5.8 (1.1) 5.7 (1.2) 5.5 (1.0) 5.8 (1.2) 5.9 (1.1) IIA vs. IIB, p = 0.026
IIA vs. IIC, p < 0.001
IA vs. IB, p = 0.013
Number of previous DMARDs 3.1 (1.7) 4.2 (2.2) 4.2 (1.9) 3.1 (1.1) 4.2 (1.8) 4.5 (2.1) IIA vs. IIB, p < 0.001
IIA vs. IIC, p < 0.001
IA vs. IB, p < 0.001
IA vs. IC, p < 0.001
VASglobal (mm) 60 (22) 70 (18) 67 (22) 60 (22) 71 (17) 66 (21) IIA vs. IIB, p = 0.001
IIA vs. IIC, p = 0.017
IA vs. IB, p < 0.001
IA vs. IC, p = 0.004
VASpain (mm) 60 (23) 70 (17) 64 (24) 60 (22) 66 (19) 65 (22) IIA vs. IIC, p = 0.020
IA vs. IB, p < 0.001
EVALglobal (mm) 57 (23) 57 (22) 58 (23) 56 (24) 56 (21) 60 (24) IIA vs. IIC, p = 0.015
MTX dosage (mg/week) 14.3 (6.0) - - 16.1 (5.0) - - IA vs. IIA, p < 0.001
CRP (mg/litre) 33.1 (34.0) 39.5 (38.7) 39.1 (36.6) 32.1 (34.5) 38.4 (30.0) 41.6 (38.0) IIA vs. IIB, p = 0.029
IIA vs. IIC, p = 0.008
ESR (mm/hour) 35.0 (24.1) 42.1 (26.8) 44.0 (28.2) 34.2 (23.1) 41.9 (25.0) 44.4 (27.1)  
  1. Values are presented as the mean (standard deviation). CRP, C-reactive protein; DAS28, 28-joint disease activity score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; EVALglobal, physician's global assessment of disease activity on a five-grade scale; HAQ, health assessment questionnaire; MTX, methotrexate; VASglobal, visual analogue scale for general health; VASpain, visual analogue scale for pain.